Completed NA INTERVENTIONAL 2-arm NCT02030769

Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer

Sponsor: Beijing Tide Pharmaceutical Co., Ltd

Updated 5 times since 2017 Last updated: Mar 28, 2016 Started: Jan 31, 2014 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Esophageal Neoplasms and is currently completed. Beijing Tide Pharmaceutical Co., Ltd leads this study, which shows 5 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Tide Pharmaceutical Co., Ltd
Xijing Hospital of Digestive Diseases

Data source: Xijing Hospital of Digestive Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xi'an, China